RxDoctor Payments Data

Howard Kraft, MD

Neurology · Chattanooga, TNNPI 1326097262

Payments from drug & device makers

$17,475in general payments, 2019–2025

Across 1,007 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$1K
  • Pfizer$857
  • Novartis$796
  • AstraZeneca$753
  • Amgen$680
  • plus $9K from 51 others

What the payments were for

  • Speaking & faculty fees$600%
  • Food & beverage$17,33099%
  • Education$850%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)292$3,845
UCB, Inc.58$1,429
Pfizer51$857
Novartis40$796
AstraZeneca(2 entities)35$753
Amgen(2 entities)31$680
Biogen42$652
Biohaven Pharmaceuticals, Inc.42$596
Bristol Myers Squibb45$585
Acadia Pharmaceuticals Inc33$567
Neurocrine Biosciences, Inc.29$540
Lundbeck LLC21$469
Lilly USA, LLC24$434
Neurelis, Inc.16$434
Teva Pharmaceuticals USA, Inc.35$407
EMD Serono, Inc.17$397
Sanofi15$336
MDD US Operations, LLC13$281
TG Therapeutics, Inc.6$280
Avanir Pharmaceuticals, Inc.14$268
CSL Behring10$233
Biohaven Pharmaceutical Holding Company Ltd.14$216
Kyowa Kirin, Inc.10$201
Eisai Inc.10$194
Supernus Pharmaceuticals, Inc.13$185
Argenx US, Inc.8$171
SK Life Science, Inc.7$170
Arbor Pharmaceuticals, Inc.8$138
Johnson & Johnson(2 entities)9$127
Axsome Therapeutics, Inc.4$104
Octapharma USA, Inc.4$85
Amneal Pharmaceuticals LLC5$79
Acorda Therapeutics, Inc4$77
Genentech USA, Inc.3$73
Sumitomo Pharma America, Inc.3$67
Jazz Pharmaceuticals Inc.2$57
Banner Life Sciences, LLC3$56
Scilex Pharmaceuticals Inc.3$53
Takeda Pharmaceuticals U.S.A., Inc.2$52
Merz Pharmaceuticals, LLC2$51
Catalyst Pharmaceuticals, Inc.2$49
Adamas Pharmaceuticals, Inc.2$43
Upsher-smith Laboratories LLC2$36
Mallinckrodt Enterprises LLC2$34
Sunovion Pharmaceuticals Inc.2$32
Alnylam Pharmaceuticals Inc.1$32
Avion Pharmaceuticals2$32
Merz North America, Inc.1$31
E.r. Squibb & Sons, L.L.C.2$30
Grifols USA, LLC1$27
Livanova USA, Inc.1$23
Medtronic1$22
Boston Scientific1$20
Corium, LLC1$19
Abbott1$18
Otsuka America Pharmaceutical, Inc.1$16
Azurity Pharmaceuticals, Inc.1$15

How this compares

$17,475 in reported general payments places this provider in the 65th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,666,429
Medicare patients
662
Services billed
44,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4638$674,680
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5036$464,632
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$460,002
Kesimpta PenOfatumumab42$346,854
Avonex Pen (4 Pack)Interferon Beta-1a18$194,109
NuplazidPimavanserin Tartrate24$169,691
QuliptaAtogepant73$99,633
Nurtec OdtRimegepant Sulfate66$96,040
AustedoDeutetrabenazine19$89,149
CopaxoneGlatiramer Acetate12$69,283
GlatopaGlatiramer Acetate15$40,320
Dimethyl Fumarate20$34,368
BriviactBrivaracetam25$32,906
Aimovig AutoinjectorErenumab-Aooe37$31,292
NeuproRotigotine31$28,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$27$674,68038 claims
CSL BehringPrivigen$233$464,63236 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$52$460,00213 claims
Acadia Pharmaceuticals IncNuplazid$567$169,69124 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$407$158,43231 claims
AbbVieQulipta, Ubrelvy$3,845$122,85890 claims
PfizerNurtec Odt, Dilantin$857$104,697103 claims
UCB, Inc.Briviact, Neupro$1,429$61,64456 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$79$2,48019 claims
Upsher-smith Laboratories LLCTopiramate$36$2,043114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 361 neurology providers in Tennessee.

Other neurology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →